Journal
AMERICAN JOURNAL OF GASTROENTEROLOGY
Volume 101, Issue 3, Pages 561-568Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1111/j.1572-0241.2006.00441.x
Keywords
-
Categories
Ask authors/readers for more resources
OBJECTIVES: In this study, we evaluated the safety and efficacy of a personalized mode of treatment for Crohn's disease (CD) by oral administration of Alequel (TM), an extract of autologous colonic proteins. METHODS: Thirty-one patients with moderate to severe CD were enrolled in a 27-wk randomized, double-blind, placebo-controlled trial. Patients were randomized to receive either a placebo or the study drug prepared from autologous colonic extract. RESULTS: Oral administration of autologous colonic proteins resulted in clinical remission (58%vs 29%; 46.6%vs 26.6%, using an intention to treat analysis, p= NS), clinical response (67%vs 43%; 53.3%vs 40%, using an intention to treat analysis, p= NS) and improved quality of life (Inflammatory Bowel Disease Questionnaire score improvement 43%vs 12%) in the drug study group, compared to placebo group. No treatment-related adverse events were noted. Only in the study-drug-treated cohort who achieved clinical remission (DR), there was a decreased number of subject-specific, antigen-directed, IFN gamma spot-forming colonies. DR subjects had a lower initial C-reactive protein level than DNOR or placebo subjects, an increased percentage of peripheral blood nature killer T cells, and an increased CD4(+)/CD8(+) T-cell ratio throughout the period of drug administration. CONCLUSIONS: Oral administration of Alequel (TM) is a safe method for treatment of patients with moderate to severe CD, and its efficacy needs to be proven. Several markers may be applicable as surrogate markers for the clinical effect.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available